Arterolane
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[(N-(2-amino-2-methylpropyl)-2-cis-dispiro(adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexan)-4"-yl]acetamide | |
| Clinical data | |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number |
664338-39-0  |
| ATC code | None |
| PubChem | CID 10475633 |
| ChemSpider |
25069705 |
| UNII |
3N1TN351VB |
| Chemical data | |
| Formula | C22H36N2O4 |
| Molar mass | 392.531 g/mol |
| |
| |
| (verify) | |
Arterolane, also known as OZ277 or RBx 11160, is a substance being tested for antimalarial activity[1] by Ranbaxy Laboratories.[2] It was discovered by US and European scientists who were coordinated by the Medicines for Malaria Venture (MMV).[3] Its molecular structure is uncommon for pharmacological compounds in that it has both a ozonide (trioxolane) group and an adamantane substituent.[4]
Phase III clinical trials of arterolane, in combination with piperaquine, began in India in 2009.[5] When clinical trial results were disappointing, the MMV withdrew support[2] and Ranbaxy continued developing the drug combination on its own.
References
- ↑ Dong, Yuxiang; Wittlin, Sergio; Sriraghavan, Kamaraj; Chollet, Jacques; Charman, Susan A.; Charman, William N.; Scheurer, Christian; Urwyler, Heinrich; et al. (2010). "The Structure−Activity Relationship of the Antimalarial Ozonide Arterolane (OZ277)". Journal of Medicinal Chemistry 53 (1): 481–91. doi:10.1021/jm901473s. PMID 19924861.
- 1 2 Blow to Ranbaxy drug research plans at LiveMint.com, Sep 21 2007
- ↑ Vennerstrom, Jonathan L.; Arbe-Barnes, Sarah; Brun, Reto; Charman, Susan A.; Chiu, Francis C. K.; Chollet, Jacques; Dong, Yuxiang; Dorn, Arnulf; et al. (2004). "Identification of an antimalarial synthetic trioxolane drug development candidate". Nature 430 (7002): 900–4. doi:10.1038/nature02779. PMID 15318224.
- ↑ In the Pipeline: "Ozonides As Drugs: What Will They Think Of Next?", by Derek Lowe; published November 23, 2009; retrieved November 17, 2015; at Sciencemag.org
- ↑ Indian company starts Phase III trials of synthetic artemisinin, May 4 2009, at the WorldWide Antimalarial Resistance Network
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.